This technology improves initial coulombic efficiency and suppresses irreversible reactions by controlling the Si-O bonding state within the silica (SiO2) matrix of silicon oxide (SiOx) using network modifiers, network formers, or non-network formers.
In conventional silicon oxide anode materials, the amorphous SiO2 matrix reacts with lithium during the initial charge to form irreversible lithium silicon oxides, resulting in a low initial coulombic efficiency of approximately 70%. Furthermore, crystallization through high-temperature heat treatment often leads to grain growth and reduced cycle life.
This technology involves mixing a silicon oxide precursor with network modifiers (such as alkali metals) and network formers or sulfur (S)-based non-network formers, followed by solid-state synthesis at 500–1,000°C, enabling the stable achievement of properties required for secondary battery anode materials.
This technology implements a composite crystal structure where P2 and O3 phases coexist by doping a Na-Ni-Mn-Fe-based layered cathode active material with Mg, Ti, and Zr, thereby mitigating lattice strain during charge/discharge cycles and improving ion mobility.
Conventional transition metal-based layered cathode materials (Na-Ni-Mn-Fe series) offer high discharge capacity but suffer from a rapid decline in capacity retention due to structural instability during repeated charge/discharge cycles.
By designing a cathode active material with a composition of Na a Ni b Mn c Fe d Mg e Ti f Zr g O h (where 0.70≤a≤0.80, etc.), this technology provides new design flexibility in the field of lithium secondary battery cathode materials.
This technology involves the Wickerhamomyces anomalus KG16 yeast strain, deposited as KACC 93336P, isolated from traditional fermented soybean products, as well as food compositions, microbial agents for fermentation, probiotic formulations, and manufacturing methods using this strain. Doenjang (soybean paste) is produced by inoculating KG16 into plant-based protein grain raw materials or meju fermented with koji mold.
Traditional fermented soybean products derive their rich flavor and aroma from a diverse range of bacteria, yeast, and mold involved in the fermentation process depending on the region and season. However, mass-produced commercial products often suffer from a lack of flavor complexity due to a limited variety of fermentation microorganisms. Another challenge has been the difficulty in securing yeast strains that remain metabolically active and enhance flavor in high-salt environments.
This technology utilizes the salt-tolerant and osmotolerant KG16 strain, which thrives in conditions of 5–15% sodium chloride and 1–2.5M sorbitol, ensuring stable performance in high-salt doenjang aging environments or low-salt doenjang using potassium chloride. Compositions fermented with this strain show enhanced fruity and vanilla-like flavor compounds such as ethyl acetate, acetic acid, and 3-methylbutanoic acid, while also exhibiting immune-boosting activity by increasing CD86 expression in dendritic cells and IL-10 secretion. Applicable to industrial doenjang and ganjang (soy sauce) production, low-salt products, fermentation starters, and probiotic ingredients, it enables the creation of differentiated products that replicate the complex aroma of traditional fermented foods while adding functional immune benefits.
This invention was developed with support from the Ministry of Science and ICT for the identification of fermentation characteristics and key microorganisms in traditional fermented soybean products based on multi-meta-omics.
본 기술은 당단풍나무(Acer pseudosieboldianum) 잎을 물, 저급알코올, 아세톤 등의 용매로 추출하거나 분획한 물질, 또는 여기서 분리한 푸니카폴린·그라나틴 B·말로투시닉산을 유효성분으로 하는 전립선암 예방·치료용 약학 조성물과 개선용 식품 조성물입니다. 이 성분들은 항산화·항염증 작용과 함께 전립선암 세포의 증식을 억제하고 세포사멸을 유도합니다.
전립선암은 수술, 방사선, 항암제 치료에 더해 안드로겐 호르몬을 차단하는 고환절제술이나 항안드로겐 제제가 쓰여 왔지만, 안드로겐과 수용체의 결합력이 높아지는 등의 이유로 내성이 생기고 여러 부작용이 뒤따르는 문제가 있었습니다. 또한 전립선암의 발병에는 유전자 프로모터의 DNA 메틸화가 깊이 관여하지만, 이를 낮추면서도 부작용이 적은 천연 소재는 거의 개발되지 않은 한계가 있었습니다.
본 기술은 당단풍나무 잎 추출물과 분획물이 DPPH 라디칼 소거, 일산화질소 생성 억제, 암세포 항증식 및 세포사멸 촉진, DNA 메틸화 억제 활성을 함께 나타내도록 구성되며, 특히 전립선암 예방의 지표가 되는 GSTP1 유전자의 메틸화를 낮춥니다. 활성 본체인 엘라지탄닌 계열 화합물 3종을 별도의 약학 조성물로도 청구해 단일 성분 의약품 개발 경로까지 열어 두었습니다. 전립선암 보조 치료제, 중장년 남성용 전립선 건강기능식품, 천연물 신약 후보 물질 개발에 적용될 수 있어 국내 자생 수종의 잎을 원료로 호르몬 차단 요법의 내성 문제를 피하는 후성유전학적 예방 소재를 확보할 수 있습니다.
This technology provides pharmaceutical and food compositions for the prevention and treatment of rheumatoid arthritis, utilizing live or heat-killed cells of the Propionibacterium freudenreichii MJ2 strain (KCCM12272P). It is safe for long-term oral administration and simultaneously suppresses joint inflammation, bone destruction, and autoantibody production.
Rheumatoid arthritis is a chronic systemic autoimmune disease where persistent inflammation of the synovial membrane leads to cartilage and bone destruction, for which there is currently no cure. Non-steroidal anti-inflammatory drugs only alleviate pain without halting disease progression and can cause gastrointestinal issues with long-term use. Immunosuppressants like TNF-α inhibitors carry risks such as latent tuberculosis, creating a need for safer alternatives. While some Lactobacillus strains have shown potential in alleviating arthritis, available options remain limited.
This technology uses live cells obtained by culturing the MJ2 strain under anaerobic conditions at 30–37°C for 45–50 hours followed by centrifugation, or heat-killed cells. It increases the anti-inflammatory cytokine IL-10, inhibits osteoclast differentiation, apoptosis, and the production of IgG, IgG1, and IgG2a antibodies, while restoring autophagy to normal levels. Live and heat-killed cells are formulated at concentrations of 1×10⁶ to 1×10¹⁰. Applicable to oral probiotics for adjuvant therapy, functional foods for joint health, and shelf-stable postbiotic products, this strain offers a multi-pronged approach to suppressing inflammation, preventing bone damage, and reducing autoantibodies, while avoiding the infection risks associated with immunosuppressants.
This invention was developed with support from the Ministry of Science and ICT for the improvement of rheumatoid arthritis through Propionibacterium-mediated inhibition of osteoclast differentiation.
This technology provides pharmaceutical, food, and cosmetic compositions for the prevention and treatment of inflammatory diseases, using extracellular vesicles (50–150 nm in average diameter) derived from cabbage, red cabbage (Brassica), and onion (Allium) as active ingredients. It also covers a manufacturing method using juicing, ultrafiltration, and size-exclusion chromatography.
Extracellular vesicles are natural nanomaterials that transport proteins, nucleic acids, and lipids via lipid bilayers, but the biological functions and extraction methods for those derived from Brassica and Allium plants have not been systematically studied. Conventional ultracentrifugation often results in high impurity levels and potential vesicle damage, while commercial polymer precipitation faces issues with impurities and PEG contamination, limiting industrial-scale production. Furthermore, these vesicles have primarily been used as biomarkers, with few technologies leveraging their inherent efficacy.
This technology involves ultrafiltering juice with a 5–15 kDa cutoff, followed by size-exclusion chromatography using gel filtration media (e.g., Superdex or Sephacryl) with a pore size of 30–75 nm, equilibrated in pH 6–8 PBS. Only the 50–150 nm fractions are collected via particle size analysis. These vesicles effectively enter cells to inhibit IL-6, IL-1β, and COX-2 expression. Applicable to digestive health foods, skincare for acne or atopic dermatitis, and oral drug delivery, this method enables high-purity, large-scale production of anti-inflammatory vesicles from common vegetables without centrifugation or PEG.
This technology utilizes an extract obtained by room-temperature extraction of the invasive cordgrass (Spartina anglica)—which encroaches on West Coast tidal flats—using 70% ethanol by weight. The resulting extract serves as an active ingredient in cosmetic, pharmaceutical, topical, quasi-drug, and health supplement compositions for treating inflammation and atopic dermatitis. This extract contains iso-orientin, a flavonoid-based antihistamine.
Skin inflammation, including atopic dermatitis, is linked to inflammatory cytokines such as IL-6, IL-8, and IL-1β. Due to the unclear causes of these conditions, there has been a demand for natural, low-irritation materials. Cordgrass is an invasive species designated by the IUCN; after establishing itself in southern Ganghwa Island, it has disrupted tidal flat ecosystems by displacing native halophytes like Suaeda japonica. Previously, there were no reports of using this plant as a treatment for inflammation or atopy.
This technology uses cordgrass extract at concentrations of 1.25–250㎍/ml, which inhibits the expression of atopic biomarkers TARC and MDC in keratinocytes stimulated by TNF-α and IFN-γ without showing cytotoxicity, while also suppressing inflammatory cytokines and chemokines. It can be applied to atopic skincare products like soothing creams and lotions, topical ointments and transdermal patches, and health supplements for skin inflammation. This allows for the simultaneous restoration of ecosystems and the production of high-value natural anti-inflammatory materials by repurposing a plant that previously only incurred removal costs.
This invention was developed with support from the Ministry of Education for the development of blue carbon biomass-based source materials and the establishment of a marine resource recycling platform.
This technology utilizes linalyl acetate—a fragrance ingredient used in over 1,000 tons annually in cosmetics, shampoos, soaps, and household detergents—as an active ingredient in pharmaceutical compositions and food products for the prevention and treatment of sarcopenia. Linalyl acetate increases blood IGF-1 levels, which enhances muscle fiber cross-sectional area and restores body weight lost due to sarcopenia.
Sarcopenia is a progressive systemic syndrome characterized by the loss of skeletal muscle mass and strength with age. It has become a significant public health issue, increasing economic burdens, hospital stays, and mortality rates, yet no FDA-approved therapeutic drugs currently exist. Non-pharmacological approaches like exercise and diet have yielded inconsistent results, and while linalyl acetate has been reported to have diabetes-preventive and vascular-protective effects, its efficacy for sarcopenia was previously unknown.
Focusing on the fact that IGF-1, which is essential for muscle growth, differentiation, and regeneration, promotes protein synthesis via the PI3K/Akt pathway, this technology works by using linalyl acetate to elevate blood IGF-1 levels and thicken muscle fibers. Applications include not only geriatric sarcopenia but also disuse atrophy, spinal muscular atrophy, muscular dystrophy, amyotrophic lateral sclerosis (ALS), and myasthenia gravis. It can be applied to sarcopenia treatments for the elderly, management of disuse atrophy in bedridden patients, and muscle-strengthening supplements for seniors. By repurposing a widely produced and distributed fragrance ingredient as a muscle-protective agent, development costs and raw material supply burdens are significantly reduced.
This invention was developed with support from the Ministry of Education for research into the regulatory mechanisms of aromatic natural extracts in animal models of hypertension induced by chronic stress accompanied by hypermotility of the intestines.
This technology provides pharmaceutical and health supplement compositions for the prevention and treatment of ovarian and breast cancer, utilizing chrysophanol—an anthraquinone-based natural compound primarily found in rhubarb—in combination with the PI3K/AKT inhibitor LY294002 or the ERK1/2 inhibitor U0126.
Ovarian cancer lacks early diagnostic tools and frequently develops chemotherapy resistance, leading to a recurrence rate of approximately 70% in late-stage patients. Breast cancer is the second most common and deadly malignancy in women, yet advanced cases often show poor responses to surgery or chemotherapy, accompanied by significant side effects. While the anticancer effects of related anthraquinones like emodin and rhein are known, the effects of chrysophanol on gynecological cancers had not been previously reported.
This technology leverages the ability of chrysophanol to regulate PI3K/AKT and MAPK signaling pathways, thereby inhibiting the proliferation of ovarian and breast cancer cells and increasing apoptosis in a dose-dependent manner. By combining it with targeted inhibitors that focus on the same pathways, a synergistic effect on cell death is achieved. This approach can be applied to combination therapies for recurrent ovarian cancer, the development of treatments for advanced breast cancer, and anticancer screening using animal-derived cell lines, offering a strategy that reduces the toxicity associated with synthetic anticancer drugs alone.
This invention was developed with support from the Ministry of Science and ICT for research into the role of sideroxylin extracted from Callistemon viminalis in the prevention and treatment of gynecological cancers.
This technology is an anti-influenza virus composition containing Ardisia japonica methanol extract as an active ingredient. It includes pharmaceutical compositions, health functional foods, food products, and feed compositions for the prevention and treatment of infection-related diseases such as influenza, colds, pharyngitis, bronchitis, and pneumonia, as well as methods for their preparation.
Vaccines, the cornerstone of flu prevention, are produced based on early-year predictions of winter strains, leading to reduced efficacy if the actual circulating virus differs from the vaccine antigen, and making rapid responses to unexpected novel viruses difficult. While the neuraminidase inhibitor oseltamivir was effective during the 2009 pandemic, its repeated use led to the emergence of resistant strains that spread globally, and it also has limited efficacy against influenza B viruses.
This technology blocks the initial stage of viral cell entry by having Ardisia japonica extract coat and mask hemagglutinin, a viral surface glycoprotein, preventing it from binding to cell receptors. It can utilize water, hexane, chloroform, ethyl acetate, or butyl alcohol fractions in addition to methanol extract, and targets a broad range of viruses including types A, B, and C, H1N1, and highly pathogenic H5N1. By targeting hemagglutinin rather than neuraminidase, it provides a natural infection-blocking solution effective against drug-resistant viruses, suitable for new antivirals, combination therapies, respiratory health supplements, and poultry feed additives for avian influenza.
This technology is a functional food for obesity improvement and a pharmaceutical composition for the prevention and treatment of obesity, using surface layer proteins (SLP) from Leuconostoc mesenteroides LCM8 isolated from kefir, exopolysaccharides (EPS) from Lactobacillus kefiri DH5, and grape seed powder as active ingredients. It is a postbiotic approach that uses active components extracted from bacteria rather than live cultures.
While kefir is known for its cholesterol-lowering and anti-obesity effects, existing technologies use live kefir-derived lactic acid bacteria, which require the consumption of a specific number of bacteria to be effective and suffer from reduced efficiency due to bacterial loss during manufacturing, packaging, and storage. Grape seed powder, a prebiotic often used in combination, also has the disadvantage of requiring an excessively high daily intake to achieve anti-obesity effects.
This technology leverages the fact that isolating the protein layer surrounding the lactic acid bacteria provides anti-obesity and anti-inflammatory effects on its own, and when combined with exopolysaccharides from other kefir strains and grape seed powder—a byproduct of winemaking—it creates a synergy that provides sufficient efficacy even in small amounts. It can be applied to room-temperature weight management foods where maintaining live cultures is difficult, functional fermented foods like yogurt and beverages, and auxiliary pharmaceutical materials for obesity treatment, allowing for the creation of anti-obesity products that maintain consistent efficacy without concerns about bacterial count reduction and significantly lower the burden of daily intake.
This invention was developed with support from the Ministry of Science and ICT for the development of natural food materials for improving metabolic obesity diseases using a high-function complex hurdle of kefir lactic acid bacteria polysaccharides, S-proteins, and wine grape seed polyphenols.
This technology utilizes Sargassum thunbergii, a brown alga commonly found on rocky intertidal zones in Korea, extracted with 60–80 wt% ethanol to obtain an extract containing aldehyde compounds. It is used in cosmetic, pharmaceutical, topical, quasi-drug, and health supplement compositions at concentrations of 50–100 µg/ml for atopic and allergic dermatitis.
Atopic dermatitis is a chronic inflammatory skin disease characterized by persistent itching and cycles of improvement and worsening without a clear cause. As the exact etiology remains unknown, there is a growing demand for natural, low-irritation treatments. While Sargassum thunbergii has been used as an anthelmintic, food source, and fertilizer, and has shown potential anti-cancer properties, it has never before been applied to the treatment of atopic or allergic dermatitis.
This technology identifies a concentration range that inhibits the expression of TARC and MDC—reliable biomarkers for atopy—in keratinocytes where inflammation was induced by TNF-α and IFN-γ, without exhibiting toxicity to weakened cells. Extraction conditions were optimized, as concentrations below 60 wt% result in insufficient active ingredient extraction, while those above 80 wt% provide no further yield improvement. Applicable to atopic moisturizing creams, cleansers, quasi-drugs like sensitive-skin wipes and shower foams, and health supplements for skin immunity, this technology adds high value to a common, inexpensive seaweed resource as a low-irritation natural material for managing both itching and inflammation.
This invention was developed with support from the Ministry of Education for the development of blue carbon biomass-based source materials and the establishment of a marine resource recycling platform.
This technology produces "Green Fiber," an ultrafine dietary fiber powder, by separating rice bran from early-harvest green whole rice—which is rich in chlorophyll and fiber—through steaming, drying, and milling. The bran is then degreased with hexane, coarsely ground, sieved, and processed via air-jet milling.
While dietary fiber is recognized for preventing chronic diseases by improving bowel function and lowering cholesterol and blood pressure, conventional insoluble fiber materials are often coarse and bitter due to large, uneven particle sizes from standard grinding, making them difficult to use in food. Green whole rice bran has similarly been limited by its texture and taste, with little research on effective processing methods.
This technology stabilizes rice bran through brief steaming (70–100°C for 5–20 seconds) and two-stage drying. After double-degreasing with hexane and vacuum-removing residual solvents, the bran retained by a 150㎛ sieve is ultrafine-ground using a jet mill to narrow the particle size distribution. This allows rice bran—a milling byproduct—to be transformed into a premium fiber ingredient for beverages, soy milk, dairy, desserts, and senior-friendly foods, increasing fiber content without compromising texture.
This invention was developed with support from the Ministry of Agriculture, Food and Rural Affairs for the development of food materials and products using organic green whole grains.
This technology involves feeding laying hens a diet containing 1.5–2.5 wt% of Dunaliella microalgae, which is rich in lutein and zeaxanthin, to produce eggs with a lutein content of 34.9–38.9 µg per gram of yolk. These eggs contain 2.5 to 4 times more lutein and zeaxanthin than standard eggs.
Lutein and zeaxanthin are macular pigments that prevent age-related vision loss, such as macular degeneration. However, animals cannot synthesize them, and it is difficult to meet the 10mg daily recommended intake through a normal diet. Marigold flowers, the primary source, are expensive due to long cultivation periods and low yield per area, while direct extraction from microalgae often results in insufficient zeaxanthin levels. Previous attempts to accumulate these pigments in eggs via feed lacked established optimal conditions.
This technology optimizes the transfer of macular pigments to the yolk by setting the microalgae inclusion rate at 1.5–2.5 wt% and the feeding period at 7–60 days, resulting in eggs with excellent color and flavor. The eggs can be processed into yolk oil via ethanol extraction or into yolk powder through spray drying with excipients. Applicable to premium eye-health egg brands, lutein-fortified ingredients, and functional foods like mayonnaise, this method allows for the intake of both lutein and zeaxanthin through daily egg consumption without the need for costly marigold extracts.
This invention was developed with support from the Ministry of Science and ICT for the development of high-efficiency CO2-fixing microalgae through molecular biological improvement.
This technology provides pharmaceutical compositions and health functional foods for pain suppression and prevention, containing 5-methacrylamidoisophthalic acid derivatives represented by Formula 1, or their salts or isomers, as active ingredients. Inhibitory effects have been confirmed in models of formalin-induced pain, CFA-induced inflammatory hyperalgesia, mechanical and thermal hyperalgesia, and neuropathic pain.
Current analgesics are divided into non-steroidal anti-inflammatory drugs (NSAIDs)/COX-2 inhibitors and opioids like morphine, both of which are largely ineffective against neuropathic pain. Opioids carry risks of severe side effects and addiction at higher doses, while NSAIDs require higher dosages for efficacy and are associated with gastrointestinal side effects.
This technology is designed to alleviate both inflammatory and neuropathic hyperalgesia with a single compound, targeting a wide range of conditions including osteoarthritis, postoperative pain, cancer pain, chemotherapy-induced pain, postherpetic neuralgia, fibromyalgia, and migraines. It can be applied to treatments for neuropathic pain unresponsive to existing drugs, management of chemotherapy-induced pain, and health functional foods for chronic joint pain, offering a non-narcotic alternative that reduces reliance on opioids and NSAIDs by managing both pain types with one ingredient.
This invention was developed with support from the Ministry of Science and ICT for the development of core technologies for pain control and assessment based on input neural network molecular mechanisms.
